Medical Advocates
Tenofovir Disoproxil Fumarate (Viread)
   
Journal HIV Efficacy/Non-Efficacy
Citations

Prophylaxis
Treatment



 
Journal  Main Page Main New/Newsworthy Home Page      
Last Update:  December 13, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Prophylaxis
 
 
Tenofovir DF Plus Lamivudine or Emtricitabine for Nonoccupational Postexposure
Prophylaxis (NPEP) in a Boston Community Health Center.
Mayer KH, Mimiaga MJ, Cohen D,et al 
J Acquir Immune Defic Syndr. 2007 Dec 20
 Abstract
 
FULL-TEXT ARTICLE
 The Abandoned Trials of Pre-Exposure Prophylaxis for HIV: What Went Wrong?
Singh J,  Mills EJ 
PLOS Medicine Vol2 Issue 9 Sep 2005
 Paper
 
FULL-TEXT PDF ARTICLE
 Media reporting of tenofovir trials in Cambodia and Cameroon
Mills EJ, Rachlis B, Wu P, et al
BMC International Health and Human Rights 2005, 5:6 doi:10.1186/1472-698X-5-6
 Paper
 
The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure
prophylaxis.
 Winston A, McAllister J, Amin J, et al 
HIV Med. 2005 May;6(3):191-197
 Abstract
 
 
Treatment
 
 
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination
in naive HIV-1-infected patients.
 Rey D, Hoen B, Chavanet P,  et al  
J Antimicrob Chemother. 2008 Nov 2
 Abstract
 

A WEEK IN REVIEW FEATURED REPORT
 Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine
--a Staccato trial substudy.
Ananworanich J, Nuesch R, Côté HC, et al 
J Antimicrob Chemother. 2008 Mar 12
Abstract
 
A WEEK IN REVIEW FEATURED REPORT
The Safety and Efficacy of Switching Stavudine to Tenofovir DF in Combination with
Lamivudine and Efavirenz in HIV-1-Infected Patients: Three-Year Follow-up After
Switching Therapy.
Valdez JR, Cassetti I, Suleiman JM, et al 
HIV Clin Trials. 2007 Nov-Dec;8(6):381-90.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Randomized Controlled Trial of Once-Daily Tenofovir, Lamivudine, and Lopinavir/Ritonavir
Versus Remaining on the Same Regimen in Virologically Suppressed HIV-Infected Patients
on Their First PI-Containing HAART Regimen.
Loutfy MR, Ackad N, Antoniou T, et al  
HIV Clin Trials. 2007 Sep-Oct;8(5):259-68
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Effectiveness and Safety of Simplification Therapy with Once-Daily Tenofovir, Lamivudine,
and Efavirenz in HIV-1-Infected Patients with Undetectable Plasma Viral Load on HAART.
Arrizabalaga J, Arazo P, Aguirrebengoa K, et al
HIV Clin Trials. 2007 Sep-Oct;8(5):328-36.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
The Safety and Efficacy of Tenofovir DF in Combination with Lamivudine and Efavirenz
Through 6 Years in Antiretroviral-Naïve HIV-1-Infected Patients.
Cassetti I, Madruga JV, Suleiman JM, et al
HIV Clin Trials. 2007 May-Jun;8(3):164-72.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to
baseline resistance testing: Impact of resistant minority variants on efficacy of low genetic
barrier drugs.
Van Laethem K, De Munter P, Schrooten Y, et al 
J Clin Virol. 2007 Mar 16;
 Abstract
 
A WEEK IN REVIEW FEATURED PROFILE
Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients:
The tenoplus study.
Dominguez S, Ghosn J, Peytavin G, et al
J Med Virol. 2006 Dec 19;79(2):105-110
Abstract
 
Immunological effectiveness of the nucleoside/nucleotide analog combinations, tenofovir +
lamivudine, didanosine + lamivudine and tenofovir + didanosine, in patients with HIV
infection and sustained viral suppression.
Cervero M, Torres R, Jusdado JJ, Rodriguez-Rosado R. et al
Enferm Infecc Microbiol Clin. 2006 Aug-Sep;24(7):426-30.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Benhamou Y, Fleury H, Trimoulet P, et al 
 Hepatology. 2006 Feb 22;43(3):548-555
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Gallant JE, DeJesus E, Arribas JR, et al 
N Engl J Med. 2006 Jan 19;354(3):251-60.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Improved Lipid Profiles and Maintenance of Virologic Control in Heavily Pretreated
HIV-Infected Patients Who Switched from Stavudine to Tenofovir Treatment.
Schewe CK, Maserati R, Wassmer G, et al 
Clin Infect Dis. 2006 Jan 1;42(1):145-7.
 Abstract
 
Dose-dependent influence of didanosine on immune recovery in HIV-infected patients
treated with tenofovir.
Karrer U, Ledergerber B, Furrer H, et al
AIDS. 2005 Nov 18;19(17):1987-1994.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 High rate of virological failure in maintenance antiretroviral therapy with didanosine and
tenofovir.
Leon A, Mallolas J, Martinez E, Lazzari ED, et al 
AIDS. 2005 Oct 14;19(15):1695-7.
Abstract
 
Compromised immunologic recovery in treatment-experienced patients with HIV
infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.
Negredo E, Bonjoch A, Paredes R, et al
Clin Infect Dis. 2005 Sep 15;41(6):901-5.
Abstract
 
High virological failure rate in HIV patients after switching to a regimen with two nucleoside
reverse transcriptase inhibitors plus tenofovir.
Perez-Elias MJ, Moreno S, Gutierrez C, et al 
AIDS. 2005 Apr 29;19(7):695-8
 Abstract
 
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression
taking tenofovir and didanosine.
Barrios A, Rendon A, Negredo E,  
AIDS. 2005 Apr 8;19(6):569-575.
 Abstract
 
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-
naive patients: a 3-year randomized trial.
Gallant JE, Staszewski S, Pozniak AL,et al
JAMA. 2004 Jul 14;292(2):191-201.
 Abstract

Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection: A Randomized Trial.
Squires K, Pozniak AL, Pierone G Jr, et al
Ann Intern Med. 2003 Sep 2;139(5 Pt 1):313-20
 Abstract
 
Tenofovir: a nucleotide analog for the management of human immunodeficiency virus
infection.
 Antoniou T, Park-Wyllie LY, Tseng AL.
Pharmacotherapy 2003 Jan;23(1):29-43
 Abstract
 
Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized,
double-blind study.
Schooley RT, Ruane P, Myers RA, et al
AIDS 2002 Jun 14;16(9):1257-1263
 Abstract
 

Journal  Main Page Main New/Newsworthy Home Page      

Tenofovir Efficacy
Journal HIV Efficacy Citations